Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

MicroSectors FANG and Innovation 3X Leveraged ETNTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

MicroSectors FANG and Innovation 3X Leveraged ETN vs Neurocrine Biosciences Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.15, while Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.

FNGUNBIX
Sector
Leveraged / InverseHealth
52-Week High
$36.15$185.50
52-Week Low
$13.73$123.10
Market Cap
$16.46B
Enterprise Value
$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.19, down 4.48% on the day, with recent volatility highlighted by a 16% single-session drop on June 5, 2026. Technical indicators show a bullish moving average signal but overbought RSI levels, with key support at $32 and resistance at $34. The product's inherent leverage amplifies both gains and losses, as seen in recent performance gaps versus the underlying index.

The outlook for FNGU is highly speculative, driven by leveraged exposure to mega-cap tech stocks. Investment opportunity lies in magnified upside during strong bull markets, but risks are severe, including decay from daily rebalancing and extreme volatility. Investors face potential rapid capital erosion in downturns, as evidenced by recent sharp declines.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.

Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.

Read more on FNGU

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX